China's innovative drug out-licensing deals surpass US $100B milestone in 2025

New data reveals that the total value of China's Innovative drug out-licensing deals has surged past $100 billion in 2025 – multiplying more than 10 times since 2020.

Global partners are voting with their capital, placing big bets on Chinese biomedical innovation. The pace suggests we're witnessing not just a trend, but the birth of a new global biopharma pillar.